In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors.
about
Non-standard amino acid incorporation into proteins using Escherichia coli cell-free protein synthesisStructural basis for the drug extrusion mechanism by a MATE multidrug transporterA current perspective on applications of macrocyclic-peptide-based high-affinity ligandsSynthesis of macrocyclic organo-peptide hybrids from ribosomal polypeptide precursors via CuAAC-/hydrazide-mediated cyclizationRobust production of recombinant phosphoproteins using cell-free protein synthesisStructurally diverse cyclisation linkers impose different backbone conformations in bicyclic peptides.In vitro selection of functional lantipeptides.Genetically encoded libraries of nonstandard peptides.In vitro selection of a photo-responsive peptide aptamer using ribosome display.Technologies for the synthesis of mRNA-encoding libraries and discovery of bioactive natural product-inspired non-traditional macrocyclic peptides.Flexizyme-mediated genetic reprogramming as a tool for noncanonical peptide synthesis and drug discovery.Peptides come round: using SICLOPPS libraries for early stage drug discovery.Artificial human Met agonists based on macrocycle scaffoldsMethods for the creation of cyclic Peptide libraries for use in lead discovery.Improving cell-free protein synthesis through genome engineering of Escherichia coli lacking release factor 1Ribosomal Synthesis of Macrocyclic Peptides in Vitro and in Vivo Mediated by Genetically Encoded Aminothiol Unnatural Amino AcidsDiscovering functional, non-proteinogenic amino acid containing, peptides using genetic code reprogramming.In Vitro Selection Combined with Ribosomal Translation Containing Non-proteinogenic Amino Acids.Expanding the amino acid repertoire of ribosomal polypeptide synthesis via the artificial division of codon boxes.Tumor-targeting peptides from combinatorial libraries.A platform for constructing, evaluating, and screening bioconjugates on the yeast surface.A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets.Macrocycle peptides delineate locked-open inhibition mechanism for microorganism phosphoglycerate mutases.Highly selective inhibition of histone demethylases by de novo macrocyclic peptides.Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5.Stereochemistry Balances Cell Permeability and Solubility in the Naturally Derived Phepropeptin Cyclic Peptides.Bioinspired strategy for the ribosomal synthesis of thioether-bridged macrocyclic peptides in bacteria.Progress towards the broad use of non-peptide synthetic macrocycles in drug discovery.tRNA engineering for manipulating genetic code.Towards Tuneable Retaining Glycosidase-Inhibiting Peptides by Mimicry of a Plant Flavonol Warhead.Max-Bergmann award lecture:A RaPID way to discover bioactive nonstandard peptides assisted by the flexizyme and FIT systems.A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM.Non-competitive cyclic peptides for targeting enzyme-substrate complexes.Model foldamers: applications and structures of stable macrocyclic peptides identified using in vitro selection
P2860
Q21131315-3262C7C1-24F3-4C6E-8900-C16DBBD1AD51Q27684293-B2B98269-97DA-4520-B978-F2396D4D0BB8Q28072407-432D8BA6-7223-41BF-A01B-55BE8724C6CEQ28084617-07A1FAA9-AB3B-45D3-A7EE-C91ABC0756FEQ28267113-4D6BD471-7439-4677-BB91-ED9522A7DD3DQ34227953-1C66FDE3-D51C-4A73-AAED-8AA7F85F6505Q34251682-4873CF2A-801A-488D-B9B8-C7217D4E4C14Q34457705-83009155-090B-40AD-99FC-CFB474301BF4Q34466593-2BD1919E-059F-492E-B115-FEF53FCA810EQ34626861-EE2EF9AF-B10F-41D6-98C1-CCD83A9604B7Q34631456-5C57F0E5-818F-473C-9CB9-576606EB40B7Q35209857-253580B4-EB23-43E1-8C49-D4C76BDFB03AQ35245109-CAB8F615-4A92-4386-891C-6FB879964730Q35542409-A4393B2D-3D1F-480B-A20D-12D14B6A036EQ35566287-D03FB327-98EA-4342-88BE-E868FD6C334FQ35620228-9FA34478-B624-45FF-8F4F-053DD724E50AQ35747679-94504D2D-ADDD-432D-B5F2-4D4354F1444AQ35896248-003F0367-EA6F-47A3-8636-7B9521F6C2A0Q35965595-1294D13C-0D52-4EAE-9993-4963FA26BEF7Q36025723-8C9BBDCA-C3A1-49B6-AB77-81DA38FFFA13Q36102147-AF66878F-05C7-411F-BE53-2D178B13E3A3Q36250421-C5499E61-48FD-40DB-A661-1C6C86277BEBQ36331476-6000D60A-7ED6-4212-995E-61B72EA55BEDQ38404861-AEF25F8C-1BE9-4A06-9E04-5A2C89ECB6FFQ40054337-76AA0EA6-9362-4D8D-BCAC-BB21B04C440DQ42358786-B663A8C3-A692-4F4B-AD1C-76556328549CQ42546666-2E6CFADA-0C9B-434C-ACEA-FEB9D5DC3C78Q47849835-0EA92BFC-D8E8-48E5-BD43-14DE45925407Q47908152-B12F3533-1C49-49C0-B36E-E6494B202F6BQ48232879-BEE2E866-353F-4CC5-8A06-F26AB2224403Q48262298-3B6D57DA-2F63-4E8F-8442-1B963AD5DFD4Q51651534-3EB4AD4B-F7C1-4FE5-B568-86ACE8FC3D2EQ55083155-7533EA30-C2CB-4ED4-8849-F12FD2FFC13CQ57840920-EB06F94F-8B38-4DF4-B7FC-85629F7A1B64
P2860
In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@ast
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@en
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@nl
type
label
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@ast
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@en
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@nl
prefLabel
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@ast
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@en
In vitro selection of anti-Akt ...... isoform-selective inhibitors.
@nl
P356
P1433
P1476
In vitro selection of anti-Akt ...... o isoform-selective inhibitors
@en
P2093
Hiroaki Suga
Yuuki Hayashi
P304
P356
10.1021/CB200388K
P577
2012-01-24T00:00:00Z